Hutchison China MediTech Deuda/Patrimonio neto
¿Qué es el Deuda/Patrimonio neto de Hutchison China MediTech?
El Deuda/Patrimonio neto de Hutchison China MediTech Ltd. es 0.72
¿Cuál es la definición de Deuda/Patrimonio neto?
La relación deuda / patrimonio neto es una relación financiera que indica la proporción relativa del capital contable y la deuda utilizada para financiar los activos de una empresa.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Deuda/Patrimonio neto de compañías en Sector Health Care en LSE en comparadas con Hutchison China MediTech
¿Qué hace Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Empresas con deuda/patrimonio neto similar a Hutchison China MediTech
- Informa Plc tiene Deuda/Patrimonio neto de 0.72
- Ashok Alco-Chem tiene Deuda/Patrimonio neto de 0.72
- YASKAWA Electric tiene Deuda/Patrimonio neto de 0.72
- Warehouses De Pauw SCA tiene Deuda/Patrimonio neto de 0.72
- Warehouses De Pauw NV tiene Deuda/Patrimonio neto de 0.72
- CyanConnode plc tiene Deuda/Patrimonio neto de 0.72
- Hutchison China MediTech tiene Deuda/Patrimonio neto de 0.72
- Universal Security Instruments tiene Deuda/Patrimonio neto de 0.72
- Zimmer Biomet Inc tiene Deuda/Patrimonio neto de 0.72
- Oriental Trimex tiene Deuda/Patrimonio neto de 0.72
- Buru tiene Deuda/Patrimonio neto de 0.72
- American Homes 4 Rent tiene Deuda/Patrimonio neto de 0.72
- Langham Hospitality Investments tiene Deuda/Patrimonio neto de 0.72